Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GESIDA 10017 HPV9 vaccine immunogenicity study in HIV-infected men who have sex with men
2018-000215-24Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- May 2018
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Fundación SEIMC-GeSIDA. Primary endpoint: Seroconversion by HPV genotype at weeks 28 and 96. Started May 2018; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2018-000215-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000215-24.